Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.52 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889731 | 0.84 | MEN1 (0.57) | PLA2G7MAOAMAOBLMNAMEN1 | |
| SCHEMBL2886374 | 0.80 | APP (0.58) | MAOAMAOBLMNAMEN1KMT2A | |
| SCHEMBL6482247 | 0.80 | L3MBTL1 (0.49) | SCN9AHSD17B10SLC6A4MAOAMAOB | |
| SCHEMBL19859227 | 0.79 | SCN9A (0.49) | SCN9AHSD17B10SLC6A4MAOAMAOB | |
| SCHEMBL19970154 | 0.79 | SMN1; SMN2 (0.50) | SCN9AHSD17B10SLC6A4MAOAMAOB | |
| SCHEMBL29464960 | 0.79 | SMN1; SMN2 (0.50) | SCN9AHSD17B10SLC6A4MAOAMAOB | |
| SCHEMBL7947358 | 0.79 | HSD17B10 (0.47) | SCN9AHSD17B10SLC6A4MAOAMAOB | |
| SCHEMBL29304015 | 0.77 | KMT2A (0.53) | HSD17B10LMNAMEN1KMT2ARAB9A | |
| SCHEMBL31028768 | 0.76 | SCN9A (0.57) | SCN9AHSD17B10SLC6A4MAOAMAOB | |
| SCHEMBL31190789 | 0.76 | SCN9A (0.44) | SCN9AHSD17B10SLC6A4MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283472-B1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | UNIV INDIANA RES & TECH CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10273228-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273228-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| CN-107922377-A | Hepatitis B virus assembly effector | 美国印第安纳大学研究和技术公司 | 2018-04-17 | — | — | CN | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| EP-3283472-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | Indiana University Research&Technology Corporation (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2009041705-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009041705-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| US-20080108823-A1 | Method For Producing Thioether Compound | MSD K.K. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108823-A1 | Method For Producing Thioether Compound | MSD K.K. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108823-A1 | Method For Producing Thioether Compound | MSD K.K. (JP) | 2008-05-08 | — | — | US | disclosed |
| CN-101068777-A | Process for producing thioether compound | BANYU PHARMA CO LTD (JP) | 2007-11-07 | — | — | CN | disclosed |
| EP-1806337-A1 | METHOD FOR PRODUCING THIOETHER COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | HAVCR2, MAVS, HCCS | SCN9A 4712/4885PLA2G7 173/4885HSD17B10 1642/4885 |
| US-20080108823-A1 | Method For Producing Thioether Compound | TST, MPST, PPIP5K2 | SCN9A 4135/4885PLA2G7 2836/4885HSD17B10 2439/4885 |
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SCN9A 3101/4885PLA2G7 162/4885HSD17B10 281/4885 |
| US-10273228-B2 | Hepatitis B viral assembly effectors | HAVCR2, MAVS, HCCS | SCN9A 4712/4885PLA2G7 173/4885HSD17B10 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.